Menu
Cardiovascular Risk Profile; serum Cardiovascular Risk Profile; serum Cardiovascular Risk Profile; serum

Cardiovascular Risk Profile; serum

Cardiovascular disease (CVD) is associated with more deaths than all cancers—and more deaths in women than breast cancer. This Cardiovascular Risk Profile evaluates a thorough battery of traditional and advanced biomarkers to aid in early detection and modification of risk factors. Doctor's Data measures the activity of lipoprotein-associated phospholipase-A2 (PLAC®), as well as the true LDL culprits; oxidized LDL, small dense LDL and Lp(a), which are higher in CVD patients and correlated with the severity of CVD. A total of thirteen primary and secondary risk factors are evaluated to provide actionable information at a tremendous value. [ LEARN MORE]

Useful for:

  • Cardiovascular Disease
  • Lipid/Lipoprotein Profile
  • Heart Attack
  • Peripheral Arterial Disease
  • Stroke
  • Cardioprotective Nutrient Status
  • Inflammation

Turnaround Time

5 to 7 days

Analytes Tested

Click any analyte name for additional clinical information, including reference ranges, specimen collection, stability and rejection criteria.

List price applies when filing with insurance or Medicare, or when billing a patient directly. Prompt payment pricing applies when billing to a physician account or prepayment is received with the test.

Doctor's Data offers profiles containing multiple analytes. *Multiple analytes may be billed under a single CPT code. Many analytes can be ordered individually. Pricing may vary. Click on a specific analyte for more information or read our detailed billing and payment policies.

The CPT codes listed on our website are for informational purposes only. This information is our interpretation of CPT coding requirements and may not necessarily be correct. You are advised to consult the CPT Coding Manual published by the American Medical Association. Doctor's Data, Inc. takes no responsibility for billing errors due to your use of any CPT information from our website.

Sign in at the top of any page to view pricing and order tests. Or click here to create an account. You may also contact us for assistance placing an order.

Detailed Information

Cardiovascular disease (CVD) is associated with more deaths than all cancers—and more deaths in women than breast cancer. The Cardiovascular Risk Profile from Doctor's Data reviews a thorough battery of biomarkers to aid in early detection and reduction of risk factors before the disease progresses. The enzymatic activity of lipoprotein-associated phospholipase-A2 (PLAC®) provides an indication of very significant atherogenic disease activity, inflammation and increased risk for rupture of advanced plaque. Elevated PLAC® activity is a very strong predictor of coronary events and CD-related mortality regardless of cholesterol levels.

Risk Factors and Analysis

Lipoprotein-Related Biomarkers
Total and LDL cholesterol, total triglycerides and HDL cholesterol have traditionally been measured to gauge CVD risk. However, recent research indicates that more focused biomarkers can provide even greater insight.

For example, oxidized LDL is plaque-specific and directly involved in accelerated atherogenesis and late-stage atherosclerotic plaque instability and rupture. Small dense LDL exhibits greater penetration into the arterial wall and has a longer half-life as well as lower resistance to oxidation compared to that of large buoyant LDL. Circulating levels of these two markers are:

     1.  Strong independent CVD risk factors
     2.  Higher in CVD patients
     3.  Correlated with the severity of CVD
     4.  Not correlated with LDL cholesterol levels

In addition, levels of apolipoproteins A-1 and B, specific protein constituents of HDL and LDL, are also strong indicators of risk.

Doctor's Data profiles evaluate each of these biomarkers as well as ratios of atherogenic to anti-atherogenic lipids, lipoproteins and apolipoproteins for further insight.

Inflammation
Arterial damage is associated with the infiltration of white cells into vessel walls and inflammation, which increases blood levels of two acute phase proteins, C-reactive protein and ferritin. For example, patients with moderately elevated CRP are more likely to develop stroke, myocardial infarction and severe peripheral arterial disease. Although not specific to CVD, analysis of high sensitivity to these two proteins is valuable in a comprehensive assessment of CVD risk.